Sign in

BIXT on OTC

BIOXYTRAN, INC

BIOXYTRAN, INC is an American pharmaceutical preparations company based in Newton.2 Its shares trade on OTC under the symbol BIXT.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Clene Inc., NOMAD POWER SOLUTIONS, INC. or Anixa Biosciences Inc, or pick any stock.

  • TickerBIXT on OTC2
  • IndustryPharmaceutical Preparations2
  • HeadquartersNewton, United States2
  • Incorporated inNV3
  • Business addressC/O Bioxytran, Inc., 75 2Nd Ave, Suite 605 Ste 605, Needham, Ma 024943
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300Q3J615PTZIU4252
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressc/o Registered Agents Inc.; 732 S 6TH ST, STE, 89101 Las Vegas, United States2
  • Registered withBusiness Center (Secretary of State), E0365712008-72

See how the biggest companies compare on our leaderboards

Diseases to eliminate viruses and prolong lifespan using carbohydrate drug design.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income5678910-$1.8M in 2025+13% since 2019
-$6.0M-$4.0M-$2.0M02019: -$1.6M-$1.6M20192020: -$1.3M-$1.3M2020−22%2021: -$4.2M-$4.2M2021+232%2022: -$2.4M-$2.4M2022−42%2023: -$3.8M-$3.8M2023+56%2024: -$2.2M-$2.2M2024−42%2025: -$1.8M-$1.8M2025−17%
Net income5678910-$2.1M in 2025+14% since 2019
-$6.0M-$4.0M-$2.0M02019: -$1.9M-$1.9M20192020: -$2.5M-$2.5M2020+37%2021: -$4.0M-$4.0M2021+59%2022: -$2.5M-$2.5M2022−39%2023: -$4.5M-$4.5M2023+81%2024: -$2.4M-$2.4M2024−47%2025: -$2.1M-$2.1M2025−10%

Every line of the income statement as filed: the last 2 fiscal years, latest first.10

Period ending2025-12-312024-12-31
Research and development$454.0K$112.3K
General and administrative$648.2K$1.2M
General and administrative affiliates$740.3K$943.2K
Total operating expenses$1.8M$2.2M
Loss from operations-$1.8M-$2.2M
Loss of issuance$488.3K
Change in FV of Derivative-$216.7K$133.1K
Interest expense-$134.3K-$84.2K
Interest expense affiliate-$51.9K-$8.3K
Amortization of Intellectual Property-$11.5K-$8.0K
Debt forgiveness$133.9K
Debt discount amortization-$677.8K
Total other expenses-$280.6K-$156.9K
Net loss before provision for income taxes-$2.1M-$2.4M
Net loss-$2.1M-$2.4M
Net loss attributable to the non-controlling interest$13.3K
NET LOSS ATTRIBUTABLE TO BIOXYTRAN-$2.1M-$2.4M
Loss per common share, basic-$0.02-$0.02
Loss per common share, diluted-$0.02-$0.02
Weighted average number of common shares outstanding, basic91.8M shares138.6M shares
Weighted average number of common shares outstanding, diluted91.8M shares138.6M shares

Compare BIOXYTRAN, INC with another company

Corporate structure

BIOXYTRAN, INC sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of BIOXYTRAN, INC

  • Binder Offer Filed SC 13D/A on BIOXYTRAN, INC, latest Aug 16, 2022
  • BIOXYTRAN, INC Newton, Massachusetts, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What BIOXYTRAN, INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Deposits held (banks)$111.5K10 Dec 31, 2025

Intangibles and goodwill

ItemLatestA year beforeChange
Finite-lived intangibles, gross$176.5K10 Dec 31, 2025$153.4K10 Dec 31, 2024+15.1%
Accumulated amortization$31.4K10 Dec 31, 2025$19.9K10 Dec 31, 2024+58.1%
Finite-lived intangibles, net$145.1K10 Dec 31, 2025$133.5K10 Dec 31, 2024+8.6%

Properties, in its own words

We do not currently own any real property. We lease access to shared office space at 75 2nd Ave., Suite 605, Needham, MA 02494 on a month-to-month basis for $163 per month. We are also leasing a shared office space in Bangalore, India on a month-to-month basis for $72 per month, and storage unit in Tel-Aviv, Israel on a month-to-month basis for $620 per month. We believe these facilities are adequate for our current needs.

Item 2 of the 10-K filed Apr 15, 2026.4

Leadership

Who has led BIOXYTRAN, INC, and when. Pick a name to see everywhere that person has worked.

President

  1. John Birchard2009
  2. Dennis Cullison2010–2012
  3. Dave Quincy Farber2017

Chief financial officer

  1. Ola Soderquist2018–now
2010201520202025
Board members and other officers (17)

Former names

  • U.S. RARE EARTH MINERALS, INC.Oct 15, 2018 to Oct 30, 20183
  • U.S. RARE EARTH MINERALS, INCMay 13, 2011 to Oct 3, 20183
  • U.S. Natural Nutrients & Minerals, Inc.Sep 3, 2009 to Apr 14, 20113
  • AMERICA'S DRIVING RANGES, INC.Oct 31, 2008 to Oct 29, 20093

Timeline

  1. Aug 11, 20268-K Other events29
  2. Mar 20, 20268-K Unregistered sale of shares; Other events30
  3. Mar 13, 20268-K Change to shareholders' rights; Executive or director change; Bylaws or fiscal year changed31
  4. Mar 2, 20268-K Other events32
  5. Feb 17, 20268-K Entered a material agreement; Other events33
  6. Feb 11, 20268-K Other events34
  7. Jan 5, 20268-K Executive or director change35
  8. Dec 15, 20258-K Executive or director change36
  9. Apr 3, 20258-K Entered a material agreement; Regulation FD disclosure37
  10. Jan 22, 20258-K Entered a material agreement; Other events38
  11. Jan 13, 20258-K Earlier financial statements no longer reliable39
  12. Jan 10, 20258-K Other events40
  13. Jun 9, 2008Founded BIOXYTRAN, INC is founded2

Filings

186 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 30 major events, 90 insider forms, 1 large holders, 3 private raises, 40 other. The latest 20:

  1. Aug 14, 202610-Q EDGAR
  2. Aug 11, 20268-K EDGAR
  3. May 15, 202610-Q EDGAR
  4. Apr 15, 202610-K EDGAR
  5. Apr 1, 2026NT 10-K EDGAR
  6. Mar 20, 20268-K EDGAR
  7. Mar 13, 20268-K EDGAR
  8. Mar 2, 20268-K EDGAR
  9. Feb 17, 20268-K EDGAR
  10. Feb 11, 20268-K EDGAR
  11. Jan 5, 20268-K EDGAR
  12. Dec 15, 20258-K EDGAR
  13. Nov 18, 20254/A PRIMARY DOCUMENT EDGAR
  14. Nov 18, 20254 PRIMARY DOCUMENT EDGAR
  15. Nov 18, 20254 PRIMARY DOCUMENT EDGAR
  16. Nov 18, 20254 PRIMARY DOCUMENT EDGAR
  17. Nov 18, 20254 PRIMARY DOCUMENT EDGAR
  18. Nov 18, 20254/A PRIMARY DOCUMENT EDGAR
  19. Nov 18, 20254/A PRIMARY DOCUMENT EDGAR
  20. Nov 14, 202510-Q EDGAR

The 186 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 18, 2025Hoberman Alan MDirectorBuy210,000$0.60$126.0KForm 4
Aug 15, 2024PLATT DAVIDCEOBuy1,592,921$0.12$191.2KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Binder OfferSC 13D/A, 1 filing Aug 16, 202241

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$2.2M 2022–2022
Money received by yearMoney received by year, 2022–2022: $2.2M in all. Private raises (Form D) $2.2M.$0$1M$2M$3M2022 · Private raises (Form D): $2.2M2022
Figures by year
YearPrivate raises (Form D)Total
2022$2.2M$2.2M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Nov 28, 2022Raised $130,000 in a private offering of securities42 Form D: $6 million offered in all Form D
  2. Aug 16, 2022Raised $600,000 in a private offering of equity43 Form D: 1 investor so far Form D
  3. Jan 5, 2022Raised $1.5 million in a private offering of debt44 Form D: $1.5 million offered in all Form D

SEC filer profile

How BIOXYTRAN, INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBIOXYTRAN, INC1
  • CIK0001445815
  • Employer ID (EIN)26-27976304
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company4
  • Incorporated inNevada4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressC/O Bioxytran, Inc., 75 2Nd Ave, Suite 605 Ste 605, Needham, MA 024941
  • Phone617-494-11991
  • Shares outstanding114,695,220 as of Aug 14, 202612
  • Public float$9.3M as of Jun 30, 20254
  • AuditorFruci & Associates II, PLLC, Spokane, Washington PCAOB ID 5525; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceOct 31, 20081
  • Filings469 in all: 4 (100), 8-K (88), 10-Q (53), 5 (31), 3 (19), S-1/A (19), UPLOAD (19), 10-K (17)1
    All 35 form types

    CORRESP (15), 10-Q/A (10), SC 13D (10), NT 10-Q (9), NT 10-K (8), 424B4 (7), S-1 (7), 8-K/A (6), D (6), EFFECT (6), PRE 14C (6), DEF 14C (5), 10-K/A (4), 4/A (4), RW (4), S-8 (3), DEL AM (2), SC 13D/A (2), 3/A (1), 424B3 (1), 8-A12B (1), AW (1), DEF 14A (1), PRE 14A (1), PRER14C (1), RW WD (1), SC 14F1 (1)

  • Latest filingsAnnual report (10-K) Apr 15, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Oct 13, 2009
    Latest 8-K (8-K) Aug 11, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.001 par value per shareBIXT

From the cover page of the 10-K filed Apr 15, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

Legal proceedings

In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. Legal fees for such matters are expensed as incurred and we accrue for adverse outcomes as they become probable and estimable.

On December 29, 2025, the Company terminated an officer for cause. The officer has contested all allegations and has, so far, submitted a worker rights complaint with the state of Washington, which the Company has contested as having no foundation or basis in fact. The Company does not believe the former officer will be successful in his claim, therefore no accrual has been allocated.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
    SEC EDGAROther events
  30. 30
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
    SEC EDGAROther events
  41. 41
  42. 42
  43. 43
  44. 44